Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Income from Non-Controlling Interests: 2014-2018

Historic Income from Non-Controlling Interests for Coherus Oncology (CHRS) over the last 5 years, with Dec 2018 value amounting to -$70,000.

  • Coherus Oncology's Income from Non-Controlling Interests fell 350.00% to -$18,000 in Q3 2018 from the same period last year, while for Sep 2018 it was -$72,000, marking a year-over-year increase of 47.45%. This contributed to the annual value of -$70,000 for FY2018, which is 39.66% up from last year.
  • Coherus Oncology's Income from Non-Controlling Interests amounted to -$70,000 in FY2018, which was up 39.66% from -$116,000 recorded in FY2017.
  • Coherus Oncology's Income from Non-Controlling Interests' 5-year high stood at -$44,000 during FY2014, with a 5-year trough of -$678,000 in FY2015.
  • In the last 3 years, Coherus Oncology's Income from Non-Controlling Interests had a median value of -$116,000 in 2017 and averaged -$212,333.
  • Its Income from Non-Controlling Interests has fluctuated over the past 5 years, first plummeted by 1,440.91% in 2015, then soared by 74.28% in 2017.
  • Over the past 5 years, Coherus Oncology's Income from Non-Controlling Interests (Yearly) stood at -$44,000 in 2014, then tumbled by 1,440.91% to -$678,000 in 2015, then spiked by 33.48% to -$451,000 in 2016, then soared by 74.28% to -$116,000 in 2017, then soared by 39.66% to -$70,000 in 2018.